Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer
Varga Zsuzsanna; Cserni Gabor; Rakha Emad; Olivar Ana Aula; Matute Gustavo; Van Bockstal Mieke; Richard François; Van Diest Paul J; Kovacs Aniko; Bhargava Rohit; Schnitt Stuart; Kulka Janina; Larsimont Denis; Vincent-Salomon Anne; Zambuko Blessing; Rodriguez-Martinez Paula; Floris Giuseppe; Wesseling Jelle; Derksen Patrick WB; Fernandez Pedro Luis; Brito Maria Jose; Mueller Sophie; Berghian Anca; Christgen Matthias; Tsuda Hitoshi; Desmedt Christine; Oesterreich Steffi; Boström Pia; Kurozumi Sasagu; Franchet Camille; De Schepper Maxim; Melendez Cristina; Van Baelen Karen
Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer
Varga Zsuzsanna
Cserni Gabor
Rakha Emad
Olivar Ana Aula
Matute Gustavo
Van Bockstal Mieke
Richard François
Van Diest Paul J
Kovacs Aniko
Bhargava Rohit
Schnitt Stuart
Kulka Janina
Larsimont Denis
Vincent-Salomon Anne
Zambuko Blessing
Rodriguez-Martinez Paula
Floris Giuseppe
Wesseling Jelle
Derksen Patrick WB
Fernandez Pedro Luis
Brito Maria Jose
Mueller Sophie
Berghian Anca
Christgen Matthias
Tsuda Hitoshi
Desmedt Christine
Oesterreich Steffi
Boström Pia
Kurozumi Sasagu
Franchet Camille
De Schepper Maxim
Melendez Cristina
Van Baelen Karen
SPRINGERNATURE
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2022091358908
https://urn.fi/URN:NBN:fi-fe2022091358908
Tiivistelmä
Invasive lobular carcinoma (ILC) represents the second most common subtype of breast cancer (BC), accounting for up to 15% of all invasive BC. Loss of cell adhesion due to functional inactivation of E-cadherin is the hallmark of ILC. Although the current world health organization (WHO) classification for diagnosing ILC requires the recognition of the dispersed or linear non-cohesive growth pattern, it is not mandatory to demonstrate E-cadherin loss by immunohistochemistry (IHC). Recent results of central pathology review of two large randomized clinical trials have demonstrated relative overdiagnosis of ILC, as only similar to 60% of the locally diagnosed ILCs were confirmed by central pathology. To understand the possible underlying reasons of this discrepancy, we undertook a worldwide survey on the current practice of diagnosing BC as ILC. A survey was drafted by a panel of pathologists and researchers from the European lobular breast cancer consortium (ELBCC) using the online tool SurveyMonkey (R). Various parameters such as indications for IHC staining, IHC clones, and IHC staining procedures were questioned. Finally, systematic reporting of non-classical ILC variants were also interrogated. This survey was sent out to pathologists worldwide and circulated from December 14, 2020 until July, 1 2021. The results demonstrate that approximately half of the institutions use E-cadherin expression loss by IHC as an ancillary test to diagnose ILC and that there is a great variability in immunostaining protocols. This might cause different staining results and discordant interpretations. As ILC-specific therapeutic and diagnostic avenues are currently explored in the context of clinical trials, it is of importance to improve standardization of histopathologic diagnosis of ILC diagnosis.
Kokoelmat
- Rinnakkaistallenteet [19207]